HIV-Tb Confections Among HIV Patients
Prevalence of HIV-Tb co Infections Among HIV Patients and Their CD4+ T Cell Status-A Single Centre Study in India
調査の概要
状態
条件
詳細な説明
Introduction
HIV infection increases the susceptibility of Mycobacterium Tuberculosis (M.Tb.) infection, and hastens its progression due to changes in immune status of the patients. In fact, tuberculosis is now the most common opportunistic infection in patients, who die from AIDS. Immune response in tuberculosis and other infections induces cytokines that enhance replication of HIV, and derives the patient to full blown AIDS. the prevalence of HIV/Tb co-infections have been reported to 0.4% to 20.1% from different regions of northern part of india. India is one of the six countries, those are accounted for 60 percent new cases of tuberculosis, and the BRICS countries collectively account for approximately 50 perce
nt cases of worldwide tuberculosis. The prevalence of multidrug resistant tuberculosis(MDR-TB.) is two-threefold higher in HIV co-infected patients; as HIV infected people rapidly acquire the active disease including resistant strain of M. Tb. and rapidly transmit the disease among population including PLHIV, who in turn, manifest the active drug resistant tuberculosis.
Methods
- This is cohort study among patients of HIV, attending ART (Antiretroviral therapy) center khagaria, Bihar, India during June' 2015 to May' 2016.
- Patients enrolled at the centre were subjected to screening for Mycobacterium tuberculosis infection by doing ESR, mantoux test, chest x-ray, sputum examination for acid fast bacillus (AFB) and nucleic acid amplification test.
- HIV/Tb co infected patients were given cotrimoxazole.
- Patients' data-for example, age, sex, co infection with tuberculosis would be recorded.
- Sputum positivity, radiological features, and extra pulmonary manifestations would be recorded and statistical analysis would be done
- Statistical analysis, such as, mean, standard deviation(SD), student T test, p-values would be done. P-value significance would be measured at p < .05.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
Bihar
-
Khagaria、Bihar、インド、851204
- ART centre, Sadar Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Patients of HIV+ enrolled ART centre
Exclusion Criteria:
- Lost to follow up patients (LFU)
- Patients died before the treatment started
- Children below 5 years
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
|---|
|
HIV mono infection
HIV Patients do not have active Mycobacterium Tuberculosis infection
|
|
HIV-Tb. co infection
Patients with HIV and MycobacteriumTuberculosis co infections
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Prevalence of HIV/Tb. co Infections Among Patients of HIV Enrolled at ART Center.
時間枠:12 months
|
% Prevalence of HIV/Tb.
co infections= no.of HIV/Tb.
co infection (48)/total no. of enrolled patients of HIV including HIV/Tb.
co infections (219) x 100, i.e. 21.9%
|
12 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Comparing CD4+ T Cell Count in HIV-Tb. and HIV Cases.
時間枠:12 months
|
CD4 cell counts of HIV patients and HIV/co infection patients would be analysed by student T test, and p value would be estimated.
|
12 months
|
協力者と研究者
捜査官
- 主任研究者:Ranjan K Singh, M.D.、Physician cum nodal officer, ART centre, Khagaria, India.
出版物と役立つリンク
一般刊行物
- Getahun H, Gunneberg C, Granich R, Nunn P. HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis. 2010 May 15;50 Suppl 3:S201-7. doi: 10.1086/651492.
- Festenstein F, Grange JM. Tuberculosis and the acquired immune deficiency syndrome. J Appl Bacteriol. 1991 Jul;71(1):19-30. No abstract available.
- Global Tuberculosis Report 2016, World Health Organisation, Geneva.
- Perrin F, Breen R, Lipman M. : HIV and Tuberculosis co-infection. ABC of HIV and AIDS. Michael W, et al (ed): Wiley-Blackwell, BMJ Publishing Group Limited 6:42-47,2012
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
試験データ・資料
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。